Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Apyx Medical Corp APYX

Apyx Medical Corporation is an advanced energy technology company. The Company's segments include Advanced Energy and OEM. The Advanced Energy segment's product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It is focused on the cosmetic surgery market where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians an ability to provide controlled heat to the tissue to achieve their desired results. Its product lines consist of a multifunction generator, a handpiece and a supply of helium gas. The OEM segment leverages its expertise in the design, development and manufacturing of electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers through original equipment manufacturing agreements, as well as start-up companies with the need for its energy-based designs.


NDAQ:APYX - Post by User

Bullboard Posts
Post by JGrabaron May 30, 2020 11:19am
209 Views
Post# 31091741

$APYX - Potential Shareholder Derivative Case

$APYX - Potential Shareholder Derivative Case

A securities class action pending against APYX has survived a motion to dismiss. That case alleges that Apyx misled investors about its 2018 J-Plasma FDA application, causing Apyx's stock to trade at artificially inflated prices. 

Grabar Law Office is investigating potential derivative claims based on harm the company has suffered as a result of potential breaches of fiduciary duty by the company's officers and directors.  To learn more, message me here or email jgrabar@grabarlaw.com

Bullboard Posts